Relief Therapeutics Holding AG
Relief Therapeutics Holding AG Fundamental Analysis
Relief Therapeutics Holding AG (RLF.SW) shows moderate financial fundamentals with a PE ratio of -2.13, profit margin of -4.20%, and ROE of -49.18%. The company generates $0.0B in annual revenue with strong year-over-year growth of 39.52%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -315.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze RLF.SW's fundamental strength across five key dimensions:
Efficiency Score
WeakRLF.SW struggles to generate sufficient returns from assets.
Valuation Score
ExcellentRLF.SW trades at attractive valuation levels.
Growth Score
ExcellentRLF.SW delivers strong and consistent growth momentum.
Financial Health Score
ExcellentRLF.SW maintains a strong and stable balance sheet.
Profitability Score
WeakRLF.SW struggles to sustain strong margins.
Key Financial Metrics
Is RLF.SW Expensive or Cheap?
P/E Ratio
RLF.SW trades at -2.13 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, RLF.SW's PEG of -0.02 indicates potential undervaluation.
Price to Book
The market values Relief Therapeutics Holding AG at 1.11 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -2.57 times EBITDA. This is generally considered low.
How Well Does RLF.SW Make Money?
Net Profit Margin
For every $100 in sales, Relief Therapeutics Holding AG keeps $-4.20 as profit after all expenses.
Operating Margin
Core operations generate -2.05 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-49.18 in profit for every $100 of shareholder equity.
ROA
Relief Therapeutics Holding AG generates $-35.51 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Relief Therapeutics Holding AG generates limited operating cash flow of $-3.41M, signaling weaker underlying cash strength.
Free Cash Flow
Relief Therapeutics Holding AG generates weak or negative free cash flow of $-3.43M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.27 in free cash annually.
FCF Yield
RLF.SW converts -9.45% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-2.13
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.11
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.95
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.06
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.05
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.49
vs 25 benchmark
ROA
Return on assets percentage
-0.36
vs 25 benchmark
ROCE
Return on capital employed
-0.19
vs 25 benchmark
How RLF.SW Stacks Against Its Sector Peers
| Metric | RLF.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -2.13 | 28.31 | Better (Cheaper) |
| ROE | -49.18% | 699.00% | Weak |
| Net Margin | -420.33% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.06 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 4.05 | 2775.16 | Strong Liquidity |
| ROA | -35.51% | -14469.00% (disorted) | Weak |
RLF.SW outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Relief Therapeutics Holding AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
3.74%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
-63.52%
Industry Style: Defensive, Growth, Innovation
Declining